GB201900528D0 - Bicyclic peptide ligands specific for integrin AVB3 - Google Patents

Bicyclic peptide ligands specific for integrin AVB3

Info

Publication number
GB201900528D0
GB201900528D0 GBGB1900528.9A GB201900528A GB201900528D0 GB 201900528 D0 GB201900528 D0 GB 201900528D0 GB 201900528 A GB201900528 A GB 201900528A GB 201900528 D0 GB201900528 D0 GB 201900528D0
Authority
GB
United Kingdom
Prior art keywords
peptide ligands
ligands specific
bicyclic peptide
integrin avb3
avb3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1900528.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleRD Ltd
Original Assignee
BicycleRD Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleRD Ltd filed Critical BicycleRD Ltd
Priority to GBGB1900528.9A priority Critical patent/GB201900528D0/en
Publication of GB201900528D0 publication Critical patent/GB201900528D0/en
Priority to US17/422,938 priority patent/US20220119488A1/en
Priority to JP2021563434A priority patent/JP2022517698A/ja
Priority to PCT/GB2020/050072 priority patent/WO2020148528A1/en
Priority to CN202080020233.1A priority patent/CN113613728A/zh
Priority to EP20701836.7A priority patent/EP3965892A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GBGB1900528.9A 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin AVB3 Ceased GB201900528D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1900528.9A GB201900528D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin AVB3
US17/422,938 US20220119488A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for integrin alpha-v-beta-3
JP2021563434A JP2022517698A (ja) 2019-01-15 2020-01-15 インテグリンαvβ3に特異的な二環式ペプチドリガンド
PCT/GB2020/050072 WO2020148528A1 (en) 2019-01-15 2020-01-15 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3
CN202080020233.1A CN113613728A (zh) 2019-01-15 2020-01-15 整联蛋白αvβ3特异性的双环肽配体
EP20701836.7A EP3965892A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for integrin alpha v beta 3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1900528.9A GB201900528D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin AVB3

Publications (1)

Publication Number Publication Date
GB201900528D0 true GB201900528D0 (en) 2019-03-06

Family

ID=65528176

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1900528.9A Ceased GB201900528D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin AVB3

Country Status (6)

Country Link
US (1) US20220119488A1 (OSRAM)
EP (1) EP3965892A1 (OSRAM)
JP (1) JP2022517698A (OSRAM)
CN (1) CN113613728A (OSRAM)
GB (1) GB201900528D0 (OSRAM)
WO (1) WO2020148528A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102754019B1 (ko) 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
ES2926195T3 (es) 2017-08-04 2022-10-24 Bicycletx Ltd Ligandos peptídicos bicíclicos específicos de CD137
AU2019224659A1 (en) 2018-02-23 2020-10-15 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CA3189761A1 (en) 2020-08-03 2022-02-10 Gemma Mudd Peptide-based linkers
BR102021016135A2 (pt) * 2021-08-16 2023-02-23 Novageia Biotecnologia Ltda Antagonistas miméticos macrocíclicos com atividade biológica, seus usos e composições
CN114656525B (zh) * 2022-04-25 2024-02-02 合肥师范学院 用于癌细胞整合素的rgd环肽及其在制备肿瘤药物中的应用
WO2026002154A1 (en) * 2024-06-27 2026-01-02 Syneron Opal Cell penetrating peptide compounds and using thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
WO2009098450A2 (en) 2008-02-05 2009-08-13 Medical Research Council Methods and compositions
WO2011079015A1 (en) * 2009-12-21 2011-06-30 The Regents Of The University Of California Rgd-containing cyclic peptides
KR102754019B1 (ko) * 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
CN111032678A (zh) * 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201900527D0 (en) * 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3

Also Published As

Publication number Publication date
EP3965892A1 (en) 2022-03-16
US20220119488A1 (en) 2022-04-21
JP2022517698A (ja) 2022-03-09
CN113613728A (zh) 2021-11-05
WO2020148528A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
GB201900527D0 (en) Bicyclic peptide ligands specific for integrin avb3
ZA202100442B (en) Bicyclic peptide ligands specific for nectin-4
IL287881A (en) Ox40-specific bicyclic peptide ligands
IL283873B1 (en) Bicyclic peptide ligands specific for MT1-MMP
GB201810329D0 (en) Peptide ligands for binding to integrin avB3
GB201820295D0 (en) Bicyclic peptide ligands specific for MT1-MMP
GB201820320D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201701770D0 (en) Bicyclic peptide ligands specific for integrin AVB3
GB201800598D0 (en) Bicycle peptide ligands specific for integrin AVB3
GB201918495D0 (en) Bicyclic peptide ligands specific for il-46
GB201904632D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201905631D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201904621D0 (en) Bicyclic peptide ligands specific for PD-L1
GB201904622D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201918489D0 (en) Bicyclic peptide ligands specific for hsp90
GB201918496D0 (en) Bicyclic peptide ligands specific for klk5
GB201918497D0 (en) Bicyclic peptide ligands specific for klk7
GB201820956D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201818499D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201815684D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201918488D0 (en) Bicyclic peptide ligands specific for chymase
HK40067672A (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3
HK40067671A (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3
GB201820969D0 (en) Bicyclic peptide ligands specific for pd-l
GB201805850D0 (en) Bicyclic peptide ligands specific for cd137

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)